dBio Appoints Hubertus ‘Bert’ Hoyt as Board Advisor
LUXEMBOURG, April 24, 2025 – Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health technology, has announced the appointment of Hubertus ‘Bert’ Hoyt as its newest Board Advisor. Hoyt, a renowned sports industry expert with over 32 years of experience, will provide strategic insights to dBio’s Board, supporting its mission to revolutionize personalized healthcare and fitness technologies worldwide.

With a career spanning over three decades, Hoyt has worked with iconic sports brands and elite athletes. His experience includes 22 years at Nike, where he served as Vice President & General Manager of Nike Western Europe and EMEA. Hoyt’s leadership was instrumental in transforming Nike Germany, Global Football, and Western Europe, driving revenue growth from US$3 billion to US$7 billion in Western Europe and over US$10 billion in EMEA, with a 24% EBIT.
dBio is dedicated to empowering individuals to better understand their bodies through advanced wearable AIoT solutions. The company’s proprietary technologies include gMOTCloud, an AI-powered kinesiology wearable that captures detailed motion and gait metrics, and StethoCloud, a lightweight wearable stethoscope enabling continuous heart and respiratory monitoring with AI-enhanced noise reduction. These devices offer cloud-based analytics and virtual coaching support for healthier, safer, and more effective performance in exercise.
“During my personal and business life, I have been involved in helping athletes improve their performance and overall well-being. That’s why I decided to join dBio as an Advisor, as I believe their innovations will provide the next chapter for athlete performance and provide sports enthusiasts with precise data to improve and help them manage their overall well-being,” Hoyt said.
With more than 75 registered patents and a fully self-developed ecosystem spanning AI modeling, hardware, software, and app development, dBio delivers a comprehensive solution for performance optimization and health management. The company’s technology is supported by strategic partnerships with leaders across the medical, academic, and athletic sectors.
As dBio continues to expand its global footprint, it aims to redefine the future of personalized health and performance technology.